What Does BNB Plus (BNBX) Do? - Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Overview
BNBX is a micro-cap US Nasdaq-listed company that combines its core nucleic acid production and DNA tagging business with a BNB digital asset treasury strategy (formerly Applied DNA Sciences).
Subscribe🏢 What kind of company is BNB Plus?
BNBX (BNB Plus Corp.) is a Nasdaq-listed company headquartered in Stony Brook, New York, USA. The company was originally named Applied DNA Sciences, Inc. In October 2025, the company changed its name to BNB Plus Corp. and switched its ticker from APDN to BNBX, while adopting a BNB (Binance Coin)-based digital asset treasury strategy as its core approach.
Its legacy business is also maintained. Through its subsidiary LineaRx, the company supplies nucleic acid production solutions (LineaDNA, LineaRNAP, LineaIVT, etc.) to biopharmaceutical and diagnostics markets, and also operates a DNA tagging and detection business for industrial supply chain security and anti-counterfeiting.
How does it make money?| Business Segment | Revenue Weight | Description |
|---|---|---|
| Therapeutic DNA Production | Major | Revenue from nucleic acid production solutions such as LineaDNA, LineaRNAP, and LineaIVT through the LineaRx subsidiary |
| DNA Tagging & Security | Supplementary | Revenue from DNA tagging manufacturing and detection services for industrial supply chain anti-counterfeiting and security |
| BNB Treasury Income | Strategic | Token valuation and income through BNB holdings, DeFi operations, and Binance ecosystem strategies |
Recent annual revenue is $2.1M, with a sales growth rate of -44.8%. While the core nucleic acid and tagging business revenue stream is maintained, the key focus is how the new digital asset treasury strategy is reflected in earnings.
📐 Market Cap and Company Size
The market cap is $1.2M, roughly equal to About 0% of Samsung Electronics' market cap. The company has 26 people employees.
BNBX's market cap is $1.2M, placing it in the micro-cap category within the asset management and bio-composite sectors. The company has approximately 26 people employees, with an operating margin of -1080.6% and a return on equity (ROE) of -297.4%, reflecting a loss-making structure during its business transition phase.
📈 BNB Plus Outlook and Stock Price Trends
1-Year Price Performance
Analyst Consensus
52-Week Price RangeThe business outlook for BNBX hinges on the price movement of the BNB token, the stability of its DeFi yield strategy within the Binance ecosystem, and the revenue recovery of the LineaRx nucleic acid production business. The company has stated that it does not simply hold BNB, but is operating its treasury by combining active DeFi operations with Binance ecosystem-specific strategies to lift returns.
Earnings per share (EPS) is $-39.93 and the debt-to-equity ratio is 0.00, with BNB token prices and DeFi yield fluctuations being the key variables that move quarterly earnings. Additionally, the core nucleic acid production and DNA tagging business may see varying revenue recovery timing depending on bio and industrial security market trends.
⚔️ Key Competitive Strengths and Risks
BNBX is a micro-cap hybrid business operator that combines its core nucleic acid production and DNA tagging business with a BNB digital asset treasury strategy, making both cryptocurrency prices and core business revenue recovery simultaneous variables.
💪 Key Competitive Strengths
⚠️ Key Risks
Competitors and Related Stocks (Beneficiaries)
In the broader cryptocurrency treasury space, comparisons include the Bitcoin treasury model player MSTR (MicroStrategy), as well as various US-listed companies that have transitioned their businesses to Ethereum and other token holdings. On the exchange and infrastructure side, COIN (Coinbase Global) and HOOD (Robinhood Markets) are mentioned as broader competitors.
Related stocks with some overlap in business areas include nucleic acid and diagnostics players TMO (Thermo Fisher Scientific), DHR (Danaher), A (Agilent Technologies), CRSP (CRISPR Therapeutics), and TYL (Tyler Technologies) in industrial security and traceability.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| MSTR | Strategy Inc | $136.52 | -4.4% | $52.5B | - | 1.6 | -63.56% | - |
| COIN | Coinbase Global Inc | $178.99 | -3.1% | $47.2B | - | 3.6 | -7.85% | - |
| HOOD | Robinhood Markets Inc | $117.34 | -3.9% | $105.5B | 52.0 | 11.1 | 23.56% | - |
 MARA | MARA Holdings Inc | $11.83 | +4.6% | $4.6B | - | 2.7 | -107.12% | - |
 RIOT | Riot Platforms Inc | $22.26 | +2.1% | $8.4B | - | 3.8 | -48.24% | - |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| TMO | Thermo Fisher Scientific Inc | $603.02 | -1.8% | $223.0B | 32.4 | 4.2 | 13.51% | 0.31% |
| DHR | Danaher Corp | $205.23 | -1.2% | $144.3B | 36.4 | 2.7 | 7.61% | 0.69% |
 CRSP | CRISPR Therapeutics AG | $54.78 | -1.8% | $5.3B | - | 3.0 | -26.09% | - |
✅ Investor Checkpoints
BNBX is a micro-cap stock that blends a cryptocurrency treasury strategy with its core bio business, so investors should look at token prices, DeFi yields, and core business revenue trends together rather than relying on revenue alone.
| Checkpoint | What to Check | Current Status |
|---|---|---|
| Coin BNB Holdings and Valuation | Check changes in BNB quantity held and valuation, as well as the balance trends of DeFi operations. | Confirm via filings and IR materials |
| Chart DeFi Returns | Track the quarterly returns and stability trends of DeFi operations within the Binance ecosystem. | Quarterly reports and press releases |
| DNA LineaRx Revenue | Monitor whether the core nucleic acid production solutions and DNA tagging business revenue is showing a recovery trend. | Segment revenue in quarterly reports |
| Briefcase Capital Raising and Listing Maintenance | Track changes in new share issuance, capital raising, and listing maintenance-related notices. | 8-K filings and quarterly reports |
If the BNB market sours or a DeFi operational incident occurs, the company's asset value can be quickly impaired, and if core business revenue recovery is slow, there may be insufficient capacity to cushion digital asset volatility. Repeated capital raising can also accumulate the burden of equity dilution.
BNBX is a micro-cap hybrid business operator that combines its core nucleic acid production and DNA tagging business with a BNB digital asset treasury strategy. Beyond short-term revenue, a balanced tracking of BNB holdings, DeFi returns, and core business revenue trends is a meaningful starting point for valuation.
Check out real-time prices, technical indicators, and peer comparisons for BNB Plus at a glance on the US Stock Today real-time dashboard.
Subscribe Today's 5 AI picks, all free